Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Non Hodgkin Lymphoma Equipment Supplied In Europe
5 equipment items found
Manufactured by:Enterome based inParis, FRANCE
The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in indolent non-Hodgkin lymphoma (iNHL). EO2463 is being evaluated in a Phase 1/2 clinical trial as monotherapy and in combination with standard-of-care lenalidomide and/or rituximab for the treatment of ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our product is a new-generation CAP6 that shows great promise as a highly effective treatment for lung cancer (NSCLC). Lung cancer is one of the most widely prevalent cancers, and one of the most difficult to treat. Eighty-one percent of patients treated for lung cancer die within five ...
Manufactured by:Oxford Gene Technology IP Limited based inOxford, UNITED KINGDOM
The P53 probe mix consists of a 161kb probe, labelled in red that covers the whole P53 (TP53) gene and the flanking regions. The probe mix also contains a control probe for the 17 centromere (D17Z1) that is labelled in ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid leukemia (B-ALL), hairy cell leukemia, and Hodgkin’s and certain non-Hodgkin’s lymphomas. In addition to expression on ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and ...